瑋俊生物科技(00660.HK)年度收入約3.7億港元 同比減少52.2%
格隆匯12月20日丨瑋俊生物科技(00660.HK)公吿,截至2024年6月30日止年度,集團錄得收入約370.0百萬港元,較上一年度減少52.2%。收入下降主要歸因於報吿期內變性澱粉及其他生化產品的市場需求疲軟及消費量下降。此外,作為提升整體營運效率的戰略重組的一部分,集團已停止某些表現不佳的產品線。這一決定亦導致收入大幅下降。
公司擁有人應占虧損截至2024年6月30日止年度約為44.2百萬港元,而上年度的虧損約為15.4百萬港元。虧損增加主要由於報吿年度內非金融資產減值虧損的確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.